Cell and gene therapy: develop new treatments in the UK
Published 18 October 2018
漏 Crown copyright 2018
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, 皇冠体育app National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at /government/publications/cell-and-gene-therapy-develop-new-treatments-in-the-uk/cell-and-gene-therapy-develop-new-treatments-in-the-uk
皇冠体育app UK is one of the best places in the world to develop, manufacture, and commercialise cell and gene therapies.
Nearly 1 in 3 of Europe鈥檚 400 plus small and medium enterprises (SMEs) active in advanced therapy medicinal products (ATMPs) are based in the UK. 皇冠体育app number of advanced therapy companies more than doubled between 2012 and 2015.
UK cell and gene therapy infrastructure for clinical research
皇冠体育app UK has an extensive clinical trial and test bed platform in the National Health Service (NHS). 皇冠体育app NHS is the world鈥檚 largest integrated healthcare system, treating more than 60 million people.
With 拢1 billion annual invested annually, it provides a study support service for sponsors and contract research organisations (CROs). It currently hosts 60 cell and gene therapy trials.
UK platforms for cell and gene therapy technology and innovation
皇冠体育app operates 5 interdisciplinary and cross-institutional research hubs, and 5 aligned disease focused projects. 皇冠体育app focus is on bridging the gap between scienti铿乧 discovery and efforts to bring therapeutic products to the clinic. This work provides new tools, protocols, engineering solutions and knowledge to the community.
皇冠体育app provides clinical trial, technical, manufacturing, regulatory, and market access expertise to advanced therapy developers and the wider supply chain.
皇冠体育app catapult:
- aims to build an 拢10 billion industry
- has invested 拢125 million in a development facility in London with 120 staff, and in a large scale manufacturing centre in Stevenage
- works with 200 commercial and academic partners from 24 countries
Cell and gene therapy product development and manufacture in the UK
皇冠体育app UK鈥檚 offer is built on connectivity, innovation, talent, speed, compliance, value, and global access.
22 good manufacturing practice (GMP) facilities operate, an increase of 50% since 2013. 皇冠体育appre is an expanding commercial contract manufacturing capability and supply chain.
皇冠体育app offers modular manufacturing facilities for advanced therapy developers.
Industry accesses expertise in cell tissue collection and logistics through and the .
UK鈥檚 internationally recognised regulation and standards
皇冠体育app UK鈥檚 compliance culture is a major factor in enabling successful product development by:
- minimising the risk of potential supply disruption
- satisfying local and global market requirements
皇冠体育app Medicines and Healthcare Products Regulatory Agency (MHRA) provides pragmatic support and innovation when regulating for advanced therapies. 皇冠体育app MHRA Innovation Of铿乧e offers a regulatory 鈥榦ne stop shop鈥� for developers.
Global standards are set through the (NIBSC).
Contact Life Sciences Organisation (LSO)
LSO is made up of a mixed team of civil servants and private sector specialists based in the UK鈥檚 Department for International Trade (DIT).
It provides support for:
- UK life sciences companies doing business overseas
- foreign life sciences companies wanting to invest in the UK
Contact LSO for more information on commercial opportunities in the UK鈥檚 life sciences sector.
You can find out more about investing in the UK at .